Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Ranks of sales reps thinning
Fewer reps are knocking on doctors' doors these days. A consulting firm that advises most of Big Pharma says Pfizer, Sanofi-Aventis, and Bristol-Myers Squibb have all culled their herds of reps. And more companies will be following suit soon.
The cuts aren't a huge surprise; when most of the big drugmakers announced their restructuring-slash-layoff plans, they drew big targets on their sales operations. But other factors come into play, too, Jaideep Bajaj of ZS Associates told the WSJ Health Blog. Companies are backing away from their old, blanket-the-market sales models. Instead of sending five reps to chat up a doctor about the same med, they're sending only two or three.
- read the Health Blog item
- see a video interview with Bajaj
Related Articles:
Top 8 layoffs of 2007. Report
Pfizer to axe 2,200 sales jobs in realignment. Report
What to do with Avandia sales force? Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


